Patents by Inventor Susan Fennewald

Susan Fennewald has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Guanosine-rich oligonucleotide integrase inhibitors
    Patent number: 6355785
    Abstract: A method and compositions for treating viral infection (IV) vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: March 12, 2002
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan, Yves Pommier, Abhijit Mazumder
  • Anti-viral guanosine-rich oligonucleotides and method of treating HIV
    Patent number: 6323185
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotide. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity and integrase inhibition activity.
    Type: Grant
    Filed: July 17, 1996
    Date of Patent: November 27, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan
  • Anti-viral guanosine-rich oligonucleotides
    Patent number: 6184369
    Abstract: The oligonucleotides have sufficient guanosine to form a guanosine tetrad and can be composed of at least about 40% guanosine nucleotides, the nucleotide sequence containing at least two runs of at least two guanosines. Some of the new oligonucleotides also contain phosphorothioate backbones and 3′ end modifications. Representative guanosine-rich oligonucleotides of the present invention demonstrate anti-viral activity in tissue culture against HSV-2, HIV-1, HCMV and FMLV, and show specific inhibition of bacterial RNA polymerase enzymes T7 and T3, the FMLV and HIV-1 reverse transcriptase enzyme and eukaryotic RNA polymerase.
    Type: Grant
    Filed: October 23, 1995
    Date of Patent: February 6, 2001
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Oiwana, Michael E. Hogan
  • Anti-viral guanosine-rich oligonucleotides
    Patent number: 6150339
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides have sufficient guanosine to form a guanosine tetrad. They can be composed of at least about 40% guanosine nucleotides. Also provided are oligonucleotides of at least two runs of at least two guanosines. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
    Type: Grant
    Filed: December 9, 1997
    Date of Patent: November 21, 2000
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang, Michael E. Hogan
  • Anti-viral guanosine-rich oligonucleotides
    Patent number: 5567604
    Abstract: A method and compositions for treating viral infection in vitro and in vivo using a guanosine-rich oligonucleotides. The oligonucleotides are composed of at least about 50% guanosine nucleotides. Also provided are guanosine-rich oligonucleotides and methods for treating viral infections in humans, and a method for designing guanosine-rich oligonucleotides having anti-viral activity.
    Type: Grant
    Filed: October 28, 1993
    Date of Patent: October 22, 1996
    Assignee: Aronex Pharmaceuticals, Inc.
    Inventors: Robert F. Rando, Susan Fennewald, Joseph G. Zendegui, Joshua O. Ojwang